UPDATE: Piper Sandler Starts Vaxart Inc. (VXRT) at Overweight

June 11, 2021 4:16 AM EDT
Get Alerts VXRT Hot Sheet
Price: $2.13 -8.58%

Rating Summary:
    5 Buy, 1 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 11 | New: 34
Join SI Premium – FREE
(Updated - June 11, 2021 10:12 AM EDT)

Piper Sandler analyst Yasmeen Rahimi initiates coverage on Vaxart Inc. (NASDAQ: VXRT) with a Overweight rating and a price target of $18.00.

The analyst commented, "We are initiating coverage on Vaxart, Inc (VXRT) with an Overweight rating and $18 price target. VXRT is a clinical-stage biotech developing seven oral vaccines: five in the clinic for COVID-19, norovirus, and influenza; and two in preclinical stages for RSV and HPV.At the core is VAAST, a thoughtfully designed, novel adenoviral type5 + TLR3-adjuvant platform, providing six key advantages (pgs 9-11). Notably, Ad5 is validated in 200 clinical studies, de-risking the vector for approval due to regulator familiarity. Additionally, VAASThas been significantly de-risked through five clinical datasets showing safety and efficacy in 580 healthy patients, increasing our conviction in an insulated pipeline with potent and safe drug candidates, which gives a high success rate to seven catalysts through 2022."

For an analyst ratings summary and ratings history on Vaxart Inc. click here. For more ratings news on Vaxart Inc. click here.

Shares of Vaxart Inc. closed at $7.17 yesterday.

You May Also Be Interested In

Related Categories

Analyst Comments, Hot New Coverage, New Coverage